Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

The story of the pharmaceutical company Moderna almost reads like a Hollywood screenplay. In its relatively short life, it ...

Moderna’s third quarter was shaped by sharply lower demand for COVID-19 vaccines, yet the company delivered results above ...

Q3 earnings beat estimates but pipeline setback and lower 2025 guidance raise concerns. Full analysis of results and outlook.

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

In the past week, Moderna reported third-quarter 2025 earnings with revenue at US$1.02 billion, down sharply from the ...

In this week's STATus Report, STAT reporters Jason Mast and Damian Garde discuss the challenges facing Moderna — and what could be in store for its third act.

The S&P 500 Healthcare sector (XLV) experienced a slight rise in average short interest during October, moving from 1.91% to ...

The 9 therapeutics stocks we track reported a mixed Q3. As a group, revenues beat analysts’ consensus estimates by 5.7%. In ...

Mixed options sentiment in Moderna (MRNA), with shares down $1.15 near $25.56. Options volume running well above average with 49k contracts traded ...

Nearly two dozen life sciences companies that were awarded Massachusetts tax incentives to create and retain about 1,000 ...

Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March ...